X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9314) 9314
Magazine Article (42) 42
Book Chapter (26) 26
Book Review (9) 9
Book / eBook (3) 3
Publication (2) 2
Reference (1) 1
Streaming Video (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (8931) 8931
science & technology (6496) 6496
life sciences & biomedicine (6431) 6431
fibrinolytic agents - therapeutic use (5533) 5533
fibrinolytic agents - adverse effects (4675) 4675
male (4445) 4445
female (4347) 4347
aged (3363) 3363
middle aged (3362) 3362
fibrinolytic agents - administration & dosage (3026) 3026
cardiovascular system & cardiology (2925) 2925
treatment outcome (2830) 2830
risk factors (2137) 2137
adult (1737) 1737
peripheral vascular disease (1722) 1722
cardiac & cardiovascular systems (1466) 1466
time factors (1432) 1432
aged, 80 and over (1409) 1409
neurosciences & neurology (1286) 1286
stroke (1278) 1278
thrombolytic therapy - adverse effects (1218) 1218
tissue plasminogen activator - therapeutic use (1192) 1192
hemorrhage - chemically induced (1165) 1165
stroke - drug therapy (1142) 1142
anticoagulants - therapeutic use (1135) 1135
tissue plasminogen activator - adverse effects (1101) 1101
retrospective studies (1099) 1099
thrombolytic therapy (982) 982
clinical neurology (970) 970
anticoagulants - adverse effects (959) 959
myocardial infarction - drug therapy (959) 959
tissue plasminogen activator - administration & dosage (958) 958
general & internal medicine (906) 906
thrombolytic therapy - methods (861) 861
animals (852) 852
risk assessment (847) 847
surgery (837) 837
platelet aggregation inhibitors - therapeutic use (833) 833
hematology (829) 829
thrombolysis (813) 813
anticoagulants (793) 793
care and treatment (779) 779
prospective studies (723) 723
medicine, general & internal (705) 705
drug therapy, combination (682) 682
fibrinolytic agents - pharmacology (681) 681
thrombosis - drug therapy (680) 680
thrombosis (678) 678
heparin - therapeutic use (663) 663
pharmacology & pharmacy (628) 628
brain ischemia - drug therapy (622) 622
aspirin - therapeutic use (616) 616
heparin - adverse effects (609) 609
thrombosis - etiology (608) 608
tissue plasminogen activator (607) 607
drug therapy (596) 596
abridged index medicus (590) 590
platelet aggregation inhibitors - adverse effects (590) 590
follow-up studies (578) 578
anticoagulants - administration & dosage (564) 564
medicine & public health (559) 559
mortality (549) 549
acute disease (539) 539
neurosciences (529) 529
thrombosis - prevention & control (526) 526
randomized controlled trials as topic (522) 522
analysis (465) 465
ischemia (459) 459
aspirin (457) 457
infusions, intravenous (453) 453
stroke - etiology (450) 450
health aspects (449) 449
recombinant proteins - therapeutic use (448) 448
neurology (446) 446
clinical trials as topic (442) 442
aspirin - adverse effects (435) 435
cardiovascular (434) 434
cardiology (426) 426
stroke - prevention & control (424) 424
dose-response relationship, drug (420) 420
recurrence (418) 418
hemorrhage (414) 414
adolescent (411) 411
heart attacks (407) 407
streptokinase - therapeutic use (398) 398
pulmonary embolism - drug therapy (395) 395
thromboembolism (387) 387
practice guidelines as topic (385) 385
myocardial infarction - therapy (384) 384
drug administration schedule (383) 383
thromboembolism - prevention & control (377) 377
atrial fibrillation (376) 376
incidence (369) 369
atrial fibrillation - drug therapy (368) 368
cerebral hemorrhage - chemically induced (368) 368
prognosis (367) 367
double-blind method (346) 346
clinical trials (343) 343
stents (343) 343
administration, oral (341) 341
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8533) 8533
German (319) 319
French (203) 203
Spanish (121) 121
Italian (76) 76
Russian (65) 65
Japanese (61) 61
Swedish (30) 30
Danish (29) 29
Polish (28) 28
Norwegian (27) 27
Portuguese (26) 26
Chinese (20) 20
Dutch (16) 16
Hungarian (12) 12
Czech (11) 11
Romanian (7) 7
Serbian (7) 7
Turkish (7) 7
Finnish (4) 4
Hebrew (4) 4
Lithuanian (3) 3
Bulgarian (2) 2
Croatian (2) 2
Ukrainian (2) 2
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American journal of clinical dermatology, ISSN 1175-0561, 02/2016, Volume 17, Issue 1, pp. 11 - 22
.... The primary outcomes were complete response and time to complete response. The secondary outcomes were partial response, relapse, time to relapse, reduction of itch, the adverse event rate, and withdrawal due to adverse events... 
Life Sciences & Biomedicine | Dermatology | Science & Technology | Antifungal Agents - adverse effects | Glucocorticoids - therapeutic use | Griseofulvin - adverse effects | Photosensitizing Agents - therapeutic use | Humans | Calcitriol - adverse effects | Griseofulvin - therapeutic use | Male | Photosensitizing Agents - adverse effects | Dermatologic Agents - therapeutic use | Ficusin - therapeutic use | Administration, Cutaneous | Enoxaparin - therapeutic use | Calcitriol - therapeutic use | Lichen Planus - drug therapy | Dermatologic Agents - adverse effects | Photochemotherapy | Enoxaparin - adverse effects | Antifungal Agents - therapeutic use | Calcitriol - analogs & derivatives | Fibrinolytic Agents - adverse effects | Fibrinolytic Agents - therapeutic use | Ficusin - adverse effects | Non-Randomized Controlled Trials as Topic | Female | Acitretin - therapeutic use | Lichen Planus - radiotherapy | Acitretin - adverse effects | Glucocorticoids - adverse effects | Sulfasalazine - therapeutic use | Keratolytic Agents - therapeutic use | Lichen Planus - therapy | Keratolytic Agents - adverse effects | Treatment Outcome | Randomized Controlled Trials as Topic | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | PUVA Therapy | Sulfasalazine - adverse effects
Journal Article
Planta Medica, ISSN 0032-0943, 12/2013, Volume 79, Issue 18, pp. 1685 - 1697
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2008, Volume 372, Issue 9632, pp. 31 - 39
Summary Background The risk of venous thromboembolism is high after total hip arthroplasty and could persist after hospital discharge. Our aim was to compare... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Thiophenes - therapeutic use | Double-Blind Method | Drug Administration Schedule | Thiophenes - adverse effects | Humans | Middle Aged | Morpholines - administration & dosage | Arthroplasty, Replacement, Hip | Male | Thiophenes - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Fibrinolytic Agents - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Fibrinolytic Agents - administration & dosage | Morpholines - adverse effects | Morpholines - therapeutic use | Health care | Medical imaging | Hospitals | Protease inhibitors | Surgery | Tomography | Joint surgery | Drug therapy | Patients | Veins & arteries | Index Medicus | Abridged Index Medicus | Thiophenes/administration & dosage/adverse effects/therapeutic use | use | Arthroplasty | Replacement | Venous Thromboembolism/prevention & control | Morpholines/administration & dosage/adverse effects/therapeutic use | Kirurgi | Hip | 80 and over | Enoxaparin/administration & dosage/adverse effects/therapeutic use | Fibrinolytic Agents/administration & dosage/adverse effects/therapeutic
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2011, Volume 29, Issue 8, pp. 986 - 993
Journal Article
Journal of hepatology, ISSN 0168-8278, 2013, Volume 59, Issue 2, pp. 358 - 366
Summary Until recently, it was widely accepted that patients with cirrhosis have a bleeding tendency related to the changes in the hemostatic system that occur... 
Gastroenterology and Hepatology | Arterial thrombosis | Cirrhosis | Treatment | Anticoagulant drugs | Venous thrombosis | Thrombosis | Portal vein thrombosis | DIRECT THROMBIN INHIBITOR | ANTIPLATELET AGENTS | PORTAL-VEIN THROMBOSIS | DABIGATRAN ETEXILATE | VENOUS THROMBOEMBOLISM | MOLECULAR-WEIGHT HEPARIN | CARDIOVASCULAR-DISEASE | HEPATIC IMPAIRMENT | ANTICOAGULANT ACTIVITY | STAGE LIVER-DISEASE | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Thiophenes - therapeutic use | Thiophenes - adverse effects | Humans | Heparin - therapeutic use | Dabigatran | Heparin - adverse effects | Fibrinolytic Agents - adverse effects | Rivaroxaban | Vitamin K - antagonists & inhibitors | Fibrinolytic Agents - therapeutic use | Hemorrhage - etiology | Benzimidazoles - adverse effects | Platelet Aggregation Inhibitors - therapeutic use | beta-Alanine - analogs & derivatives | Morpholines - adverse effects | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Liver Cirrhosis - drug therapy | beta-Alanine - adverse effects | Liver Cirrhosis - complications | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Disease Progression | Animals | Thrombosis - etiology | Thrombosis - drug therapy | Drugs | Complications and side effects | Care and treatment | Liver cirrhosis
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 05/2008, Volume 99, Issue 5, pp. 830 - 839
.... This effect is best known for the PT (INR) — higher affinity for thrombin corresponds to lower molar DTI requirements to prolong the APTT... 
Direct thrombin inhibitors | Bivalirudin | direct antithrombin agents | Theme Issue Article | Direct antithrombin agents | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Recombinant Proteins - therapeutic use | Fibrinolytic Agents - chemistry | Hirudins - chemistry | Humans | Acute Coronary Syndrome - mortality | Molecular Sequence Data | Recombinant Proteins - adverse effects | Heparin - adverse effects | Angioplasty, Balloon, Coronary - adverse effects | Fibrinolytic Agents - adverse effects | Cardiac Surgical Procedures | Thrombocytopenia - drug therapy | Anticoagulants - chemistry | Fibrinolytic Agents - therapeutic use | Peptide Fragments - immunology | Thrombosis - blood | Thrombosis - prevention & control | Platelet Aggregation Inhibitors - therapeutic use | Hirudins - immunology | Amino Acid Sequence | Recombinant Proteins - chemistry | Anticoagulants - therapeutic use | Thrombocytopenia - chemically induced | Anticoagulants - adverse effects | Fibrinolytic Agents - immunology | Acute Coronary Syndrome - blood | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Acute Coronary Syndrome - drug therapy | Peptide Fragments - chemistry | Animals | Anticoagulants - immunology | Blood Coagulation - drug effects | Recombinant Proteins - immunology | Thrombosis - etiology | Hirudins - adverse effects | Peptide Fragments - adverse effects | Peptide Fragments - therapeutic use | Hemorrhage - chemically induced | Hemostasis, Surgical - methods | Index Medicus
Journal Article